Monthly
US$200
Billed every month
Betamethasone Sodium Phosphate Injection(倍他米松磷酸钠注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 applicationNo longer listed under review: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders25View records ↓
Under-review filings5View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers27View records ↓
API companies with A status7View records ↓
Chemical-drug catalogue
Loaded records: 25 holders; 2 in the quality-and-efficacy consistency-evaluation category, and 22 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 河南利华制药有限公司 | 河南润弘制药股份有限公司 | 国药准字H20265964 | 2026/09/15 | 1ml：4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 安徽美来药业股份有限公司 | 河南科伦药业有限公司 | 国药准字H20265447 | 2026/08/04 | 1ml：4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 四川美大康华康药业有限公司 | 四川美大康华康药业有限公司 | 国药准字H20264484 | 2026/05/19 | 1ml：4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆市义力医药科技有限公司 | 新乡市常乐制药有限责任公司 | 国药准字H20263689 | 2026/03/25 | 1ml：4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南龙海天然植物药业有限公司 | 西南药业股份有限公司 | 国药准字H20263606 | 2026/03/17 | 1ml∶4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 吉林省辉南长龙生化药业股份有限公司 | 吉林省辉南长龙生化药业股份有限公司 | 国药准字H20263541 | 2026/03/10 | 1ml∶4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江浙北药业有限公司 | 浙江仙琚制药股份有限公司 | 国药准字H20263158 | 2026/01/20 | 1ml：4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江仙琚制药股份有限公司 | 浙江仙琚制药股份有限公司 | 国药准字H20263004 | 2026/01/05 | 1ml：4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 新乡市常乐制药有限责任公司 | 新乡市常乐制药有限责任公司 | 国药准字H20256197 | 2025/12/09 | 1ml : 4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 新乡市常乐制药有限责任公司 | 新乡市常乐制药有限责任公司 | 国药准字H20256196 | 2025/12/09 | 0.5ml : 2mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 漯河市汇创医药有限公司 | 裕松源药业有限公司 | 国药准字H20255643 | 2025/09/30 | 1ml：4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都瑞尔医药科技有限公司 | 广州绿十字制药股份有限公司 | 国药准字H20255052 | 2025/07/29 | 1ml∶4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏神龙药业有限公司 | 新乡市常乐制药有限责任公司 | 国药准字H20255017 | 2025/07/29 | 0.5ml：2mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏神龙药业有限公司 | 新乡市常乐制药有限责任公司 | 国药准字H20255016 | 2025/07/29 | 1ml：4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 汇禹远和（海南）药业有限公司 | 津药和平（天津）制药有限公司 | 国药准字H20254262 | 2025/05/27 | 1ml：4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 辰欣药业股份有限公司 | 辰欣药业股份有限公司 | 国药准字H20254363 | 2025/05/27 | 1ml:4mg(按C22H29FO5计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖北民康药业集团有限公司 | 津药和平（天津）制药有限公司 | 国药准字H20254024 | 2025/04/30 | 1ml∶4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 裕松源药业有限公司 | 裕松源药业有限公司 | 国药准字H20253583 | 2025/03/11 | 1ml∶4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 陕西丽彩药业有限公司 | 新乡市常乐制药有限责任公司 | 国药准字H20253417 | 2025/02/20 | 1ml:4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 武汉天安医药科技有限公司 | 津药和平(天津)制药有限公司 | 国药准字H20247307 | 2024/12/05 | 0.5ml：2mg（按C22H29FO5计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 武汉天安医药科技有限公司 | 津药和平(天津)制药有限公司 | 国药准字H20058307 | 2024/12/05 | 1ml：4mg（按C22H29FO5计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 津药和平（天津）制药有限公司 | 津药和平（天津）制药有限公司 | 国药准字H20249438 | 2024/11/22 | 1ml∶4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 华夏生生药业（北京）有限公司 | 华夏生生药业（北京）有限公司 | 国药准字H20244496 | 2024/07/30 | 1ml∶4mg（按C22H29FO5计） | Not stated by source | CDE |
| 北京布霖生物科技有限公司 | 华夏生生药业（北京）有限公司 | 国药准字H20244487 | 2024/07/30 | 1ml∶4mg（按C22H29FO5 计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都倍特得诺药业有限公司 | 成都倍特得诺药业有限公司 | 国药准字H20244470 | 2024/07/22 | 1ml：4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 重庆华邦制药有限公司 | 重庆华邦制药有限公司 | 国药准字H20243882 | 2024/06/04 | 1ml : 4mg（按C<sub>22</sub>H<sub>29</sub>FO<sub>5</sub>计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 遂成药业股份有限公司 | 遂成药业股份有限公司 | 国药准字H20064917 | 2023/08/29 | 1ml：4mg（按C22H29FO5计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 遂成药业股份有限公司 | 遂成药业股份有限公司 | 国药准字H20064917 | 2023/08/29 | 0.5ml：2mg（按C22H29FO5计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 成都天台山制药股份有限公司 | 成都天台山制药股份有限公司 | 国药准字H20265913 | 2026/09/08 | 1ml：4mg（按C22H29FO5计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 27 distinct approval numbers and 22 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 津药和平(天津)制药有限公司 | 国药准字H20249438 | 1ml∶4mg(按C22H29FO5计) | Category B (乙) | XH02ABB044B002010100874 | NHSA |
| 重庆华邦制药有限公司 | 国药准字H20243882 | 1ml ꞉ 4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010101003 | NHSA |
| 江苏神龙药业有限公司 | 国药准字H20255016 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010101478 | NHSA |
| 武汉天安医药科技有限公司 | 国药准字H20058307 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010101866 | NHSA |
| 四川美大康华康药业有限公司 | 国药准字H20264484 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010102087 | NHSA |
| 裕松源药业有限公司 | 国药准字H20253583 | 1ml∶4mg(按C₂₂H₂₉FO₅ 计) | Category B (乙) | XH02ABB044B002010103163 | NHSA |
| 遂成药业股份有限公司 | 国药准字H20064917 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010103204 | NHSA |
| 新乡市常乐制药有限责任公司 | 国药准字H20256197 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010103216 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20254363 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010104127 | NHSA |
| 山东圣鲁制药有限公司 | 国药准字H20065249 | 1ml:2.63mg(相当于倍他米松2mg) | Category B (乙) | XH02ABB044B002010104207 | NHSA |
| 浙江仙琚制药股份有限公司 | 国药准字H20263004 | 1ml:4mg(按C₂₂H₂₉FO₅ 计) | Category B (乙) | XH02ABB044B002010104735 | NHSA |
| 云南龙海天然植物药业有限公司 | 国药准字H20263606 | 1ml∶4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010106286 | NHSA |
| 华夏生生药业(北京)有限公司 | 国药准字H20244496 | 1ml∶4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010109910 | NHSA |
| 成都倍特得诺药业有限公司 | 国药准字H20244470 | 1ml :4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010182338 | NHSA |
| 陕西丽彩药业有限公司 | 国药准字H20253417 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010183540 | NHSA |
| 汇禹远和(海南)药业有限公司 | 国药准字H20254262 | 1ml꞉4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010183867 | NHSA |
| 北京六环药业有限公司 | 国药准字H20244487 | 1ml∶4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010183878 | NHSA |
| 武汉天安医药科技有限公司 | 国药准字H20247307 | 0.5ml:2mg(按C22H29FO5计) | Category B (乙) | XH02ABB044B002010184397 | NHSA |
| 安徽美来药业股份有限公司 | 国药准字H20265447 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010184482 | NHSA |
| 成都瑞尔医药科技有限公司 | 国药准字H20255052 | 1ml∶4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010184534 | NHSA |
| 湖北民康药业集团有限公司 | 国药准字H20254024 | 1ml∶4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010184564 | NHSA |
| 重庆市义力医药科技有限公司 | 国药准字H20263689 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010184778 | NHSA |
| 重庆华邦制药有限公司 | 国药准字H20243882 | 1ml ꞉ 4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010201003 | NHSA |
| 武汉天安医药科技有限公司 | 国药准字H20058307 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010201866 | NHSA |
| 裕松源药业有限公司 | 国药准字H20253583 | 1ml∶4mg(按C₂₂H₂₉FO₅ 计) | Category B (乙) | XH02ABB044B002010203163 | NHSA |
| 遂成药业股份有限公司 | 国药准字H20064917 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010203204 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20254363 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010204127 | NHSA |
| 山东圣鲁制药有限公司 | 国药准字H20065249 | 1ml:2.63mg(相当于倍他米松2mg) | Category B (乙) | XH02ABB044B002010204207 | NHSA |
| 浙江仙琚制药股份有限公司 | 国药准字H20263004 | 1ml:4mg(按C₂₂H₂₉FO₅ 计) | Category B (乙) | XH02ABB044B002010204735 | NHSA |
| 成都倍特得诺药业有限公司 | 国药准字H20244470 | 1ml :4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010282338 | NHSA |
| 陕西丽彩药业有限公司 | 国药准字H20253417 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010283540 | NHSA |
| 武汉天安医药科技有限公司 | 国药准字H20247307 | 0.5ml:2mg(按C22H29FO5计) | Category B (乙) | XH02ABB044B002010284397 | NHSA |
| 安徽美来药业股份有限公司 | 国药准字H20265447 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010284482 | NHSA |
| 成都瑞尔医药科技有限公司 | 国药准字H20255052 | 1ml∶4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010284534 | NHSA |
| 武汉天安医药科技有限公司 | 国药准字H20058307 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010301866 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20254363 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010304127 | NHSA |
| 辰欣药业股份有限公司 | 国药准字H20254363 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002010404127 | NHSA |
| 江苏神龙药业有限公司 | 国药准字H20255017 | 0.5ml:2mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002020101478 | NHSA |
| 漯河市汇创医药有限公司 | 国药准字H20255643 | 1ml:4mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002020103163 | NHSA |
| 遂成药业股份有限公司 | 国药准字H20237102 | 0.5ml:2mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002020103204 | NHSA |
| 新乡市常乐制药有限责任公司 | 国药准字H20256196 | 0.5ml:2mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002020103216 | NHSA |
| 山东圣鲁制药有限公司 | 国药准字H20065250 | 1ml:5.26mg(相当于倍他米松4mg) | Category B (乙) | XH02ABB044B002020104207 | NHSA |
| 遂成药业股份有限公司 | 国药准字H20237102 | 0.5ml:2mg(按C₂₂H₂₉FO₅计) | Category B (乙) | XH02ABB044B002020203204 | NHSA |
| 山东圣鲁制药有限公司 | 国药准字H20065250 | 1ml:5.26mg(相当于倍他米松4mg) | Category B (乙) | XH02ABB044B002020204207 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 5 filings and 5 distinct first applicants.
Generic 4 · Supplement 1
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 弘健制药（上海）有限公司;上海新华联制药有限公司 | CYHS2601687 | Generic | 2026/07/15 | Not stated by source | CDE |
| 江西科为制药有限公司;新乡市常乐制药有限责任公司 | CYHS2600995 | Generic | 2026/04/28 | Not stated by source | CDE |
| 河南润弘制药股份有限公司 | CYHS2600316 | Generic | 2026/01/30 | Not stated by source | CDE |
| 安徽均大高科医药科技有限公司;津药和平（天津）制药有限公司 | CYHS2502807 | Generic | 2025/08/04 | Not stated by source | CDE |
| 成都瑞尔医药科技有限公司;四川美大康华康药业有限公司;广州绿十字制药股份有限公司 | CYHB2601954 | Supplement | 2026/10/23 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 弘健制药（上海）有限公司;上海新华联制药有限公司 | CYHS2601687 | Generic | 2026/07/15 | Not stated by source | CDE |
| 江西科为制药有限公司;新乡市常乐制药有限责任公司 | CYHS2600995 | Generic | 2026/04/28 | Not stated by source | CDE |
| 河南润弘制药股份有限公司 | CYHS2600316 | Generic | 2026/01/30 | Not stated by source | CDE |
API registrations
Non-component matches: 7 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 倍他米松磷酸钠 | 四川仁安药业有限责任公司 | Y20240001492 | A | Exact ingredient | 2026/11/04 | CDE |
| 倍他米松磷酸钠 | 河南利华制药有限公司 | Y20230000084 | A | Exact ingredient | 2025/10/27 | CDE |
| 倍他米松磷酸钠 | CURIA SPAIN S.A.U. | Y20230001012 | A | Exact ingredient | 2026/07/13 | CDE |
| 倍他米松磷酸钠 | 上海新华联制药有限公司 | Y20190009520 | A | Exact ingredient | 2025/02/20 | CDE |
| 倍他米松磷酸钠 | 浙江仙琚制药股份有限公司 | Y20190007551 | A | Exact ingredient | 2025/11/10 | CDE |
| 倍他米松磷酸钠 | 重庆胜凯制药有限公司 | Y20190006978 | A | Exact ingredient | 2025/08/09 | CDE |
| 倍他米松磷酸钠 | 津药药业股份有限公司 | Y20170002316 | A | Exact ingredient | 2026/01/24 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/06No longer listed under review
陕西顿斯制药有限公司
CYHS2500399
Fact date: 2026/11/06 · Site observation date: 2026/11/06
Accepted: 2025/01/22
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗ -
2026/10/23Accepted
成都瑞尔医药科技有限公司;四川美大康华康药业有限公司;广州绿十字制药股份有限公司
CYHB2601954
Fact date: 2026/10/23 · Site observation date: 2026/10/24
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Betamethasone Sodium Phosphate Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy